Dr. Goldenberg reviews the risks associated with some biological agents, which had been heralded as a breakthrough in the treatment of certain medical conditions.
You are here
P&T® Journal contents for January 2004
Advances in Treating Crohn’s Disease, Rheumatoid Arthritis, and Ankylosing Spondylitis: The “Dark Side” of Anti–Tumor Necrosis Factor Therapy
The authors describe a pilot study during which many interventions resulted in a cost savings of more than $124,000 and enhanced patient care.
The authors explain how developing new guidelines at one hospital has improved the quality of care and has reduced the length of stay for patients with community-acquired pneumonia.
Dr. Greengold discusses a moral and intellectual dilemma faced by P&T committees everywhere: deciding when there is enough evidence to add a drug to the formulary.
Editorial Board Spotlight